Farther Finance Advisors LLC Has $47,000 Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 123.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,575 shares of the company’s stock after purchasing an additional 1,976 shares during the quarter. Farther Finance Advisors LLC’s holdings in Takeda Pharmaceutical were worth $47,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets increased its position in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $52,000. Finally, Cromwell Holdings LLC acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $61,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.2 %

TAK stock opened at $15.20 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $48.35 billion, a PE ratio of 37.99, a PEG ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.31. The business’s 50 day simple moving average is $13.96 and its 200 day simple moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.